Aliskiren

Renin inhibitor, antihypertensive

Signals from filings dated May 2026 – May 2026 · Last checked 15 Nov 2026

Supply outlook

↓ SHRINKING

In the filings we track: 0 plants adding this molecule, 1 exit signal, 0 intermediate projects.

↑ Coming in0 plants0 t/yr, where filed in tonnes
↓ Leaving1drops, cuts, surrenders
⇄ Own intermediates0no KSM projects found
Furthest stageEIA approvedapproval is not production

Signals

Tonghai 4th Road No. 2, Yangkou Chemical Industrial Park (West), Rudong, Nantong, Jiangsu

  1. ✓ EIA filed
  2. ✓ Approval notice
  3. ✓ EIA approved · 8 May 2026
  4. Next: completion check
  5. DMF / CEP

The existing aliskiren line (3.9 t/yr) is removed. The plant adds 33 t/yr of anti-inflammatory and anti-tumour APIs and 16 t/yr of CDMO APIs; the approval does not name those molecules. Approval No. 通数据审批〔2026〕130号, 8 May 2026. Source: EIA approval, Nantong Data Bureau

Why capacity is shown as filed →

Who makes Aliskiren today: 13 listings

Current manufacturers with US DMF and CEP status, plant addresses and contacts.

See all manufacturers →
ManufacturerCountryUS DMFCEPContact
CHANGZHOU PHARMACEUTICAL FACTORYChina✓—In database
Nosch Labs Pvt LtdIndia✓—In database
Tecoland Corp.United States——In database
+ 10 more listings in api-fdf.com →

Three examples from the api-fdf.com database, refreshed weekly. Plant addresses and contacts are shown in the database.

Follow Aliskiren

Get an email when a new filing adds, cuts or moves this molecule to the next stage.

Follow

Other molecules with signals